Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study
The Prostate · 2024
DOI: 10.1002/pros.24774 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Prostate, 2024. Verfasst von Tanxin Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Multiple novel protein biomarkers have been shown to be associated with prostate cancer risk using genetic instruments. This study aimed to externally validate the associations of 30 genetically predicted candidate proteins with prostate cancer risk using aptamer‐based levels in US Black and White men in the Atherosclerosis Risk in Communities (ARIC) study. Plasma protein levels were previously measured by SomaScan® using the blood collected in 1990–1992.
Methods
Among 4864 eligible participants, we ascertained 667 first primary prostate cancer cases through 2015. Hazard ratios (HRs) of prostate cancer and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression for tertiles of each protein. We adjusted for age, race, and other risk factors.
Results
Of the 30 proteins and considering a nominal p trend < 0.05, two were positively associated with prostate cancer risk—RF1ML (tertile 3 vs. 1: HR = 1.23; 95% CI 1.02–1.48; p trend = 0.037) and TPST1 (1.28, 95% CI 1.06–1.55; p trend = 0.0087); two were inversely associated—ATF6A (HR = 0.80, 95% CI 0.65–0.98; p trend = 0.028) and SPINT2 (HR = 0.74, 95% CI 0.61–0.90; p trend = 0.0025). One protein, KDEL2, which was nonlinearly associated (test‐for‐linearity: p < 0.01) showed a statistically significant lower risk in the second tertile (HR = 0.79, 95% CI 0.65–0.95). Of these five, four proteins—ATF6A, KDEL2, RF1ML, and TPST1—were consistent in the direction of association with the discovery studies.
Conclusion
This study validated some pre‐diagnostic protein biomarkers of the risk of prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- University of Minnesota Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
ORCID-Profile: Corinne E Joshu, Lang Wu, Elizabeth A Platz
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Liu, T., Joshu, C. E., Lu, J., Prizment, A., Chatterjee, N., Wu, L., & Platz, E. A. (2024). Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study. The Prostate. https://doi.org/10.1002/pros.24774
Vancouver
Liu T, Joshu CE, Lu J, Prizment A, Chatterjee N, Wu L, et al. Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study. The Prostate. 2024. doi:10.1002/pros.24774
BibTeX
@article{Liu2024,
author = {Liu, Tanxin and Joshu, Corinne E and Lu, Jiayun and Prizment, Anna and Chatterjee, Nilanjan and Wu, Lang and Platz, Elizabeth A},
title = {Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24774}
}
EUVIMED